Northwest Biotherapeutics (NWBO) Short term Debt (2010 - 2025)

Northwest Biotherapeutics' Short term Debt history runs 11 years deep, the most recent figure standing at $9.4 million for Q4 2025.

• In Q4 2025, Short term Debt fell 1.69% year-over-year to $9.4 million; the TTM figure through Dec 2025 stood at $9.4 million (down 1.69% YoY), while the FY2025 annual figure was $9.4 million, down 1.69% from the prior year.
• Short term Debt for Q4 2025 stood at $9.4 million, down from $9.7 million in the prior quarter.
• The five-year high for Short term Debt was $9.7 million in Q3 2025, with the low at $7.6 million in Q2 2024.
• The 5-year median for Short term Debt is $8.7 million (2022), against an average of $8.8 million.
• The sharpest annual moves came in 2021 and 2024: Short term Debt grew 28.07% in 2021, then dropped 12.67% in 2024.
• Northwest Biotherapeutics' Short term Debt stood at $8.2 million in 2021, then gained by 5.3% to $8.7 million in 2022, then climbed by 6.0% to $9.2 million in 2023, then grew by 4.24% to $9.6 million in 2024, then decreased by 1.69% to $9.4 million in 2025.
• Business Quant data shows NWBO's Short term Debt at $9.4 million in Q4 2025, $9.7 million in Q3 2025, and $9.1 million in Q2 2025.